

RESEARCH ARTICLE

Modelling and optimal control of multi strain epidemics, with application to COVID-19

Edilson F. Arruda¹*, Shyam S. Das³, Claudia M. Dias³, Dayse H. Pastore²

1 Department of Decision Analytics and Risk, Southampton Business School, University of Southampton, Southampton, United Kingdom, **2** Department of Basic and General Disciplines, Federal Center for Technological Education Celso Suckow da Fonseca, Rio de Janeiro, Rio de Janeiro, Brazil, **3** Graduate Program in Mathematical and Computational Modeling, Multidisciplinary Institute, Federal Rural University of Rio de Janeiro, Nova Iguaçu RJ, Brazil

* These authors contributed equally to this work.

* e.f.arruda@southampton.ac.uk

OPEN ACCESS

Citation: Arruda EF, Das SS, Dias CM, Pastore DH (2021) Modelling and optimal control of multi strain epidemics, with application to COVID-19. PLoS ONE 16(9): e0257512. <https://doi.org/10.1371/journal.pone.0257512>

Editor: Yury E Khudyakov, Centers for Disease Control and Prevention, UNITED STATES

Received: May 19, 2021

Accepted: September 2, 2021

Published: September 16, 2021

Copyright: © 2021 Arruda et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting information](#) files.

Funding: This study was partly supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPq, under grant 311075/2018-5 and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES) [Finance Code 001].

Competing interests: The authors have declared that no competing interests exist.

Abstract

Reinfection and multiple viral strains are among the latest challenges in the current COVID-19 pandemic. In contrast, epidemic models often consider a single strain and perennial immunity. To bridge this gap, we present a new epidemic model that simultaneously considers multiple viral strains and reinfection due to waning immunity. The model is general, applies to any viral disease and includes an optimal control formulation to seek a trade-off between the societal and economic costs of mitigation. We validate the model, with and without mitigation, in the light of the COVID-19 epidemic in England and in the state of Amazonas, Brazil. The model can derive optimal mitigation strategies for any number of viral strains, whilst also evaluating the effect of distinct mitigation costs on the infection levels. The results show that relaxations in the mitigation measures cause a rapid increase in the number of cases, and therefore demand more restrictive measures in the future.

Introduction

Also known as COVID-19, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is believed to have appeared at the end of 2019 in Wuhan, China [1]. This new, highly transmissible virus spread rapidly around the globe, causing significant loss of life and possibly long-lasting economic consequences. The ensuing pandemic highlighted the need for comprehensive epidemic models to help shape public policy [2]. One important challenge is to reconcile inaccurate data reports and conflicting information from distinct studies [3]. Another challenge is to find general modelling frameworks to address newly discovered characteristics, such as reinfection and multiple viral strains [4–6].

Parsimonious models, such as the classical SEIR (Susceptible, Exposed, Infected, Removed), are invaluable for forecasting epidemic spread and to support decision making [7]. Indeed, SEIR belongs to the class of compartmental models introduced in the first half of the 20th century to describe the spread of transmissible diseases [8, 9]. Simple and easy to use, they were able to predict the spread of COVID-19 in US states [7] and to fit historical data of the 1918 flu

epidemic in the US [10]. Works such as [11] proved to be very useful in predicting the spread of COVID-19 in different countries and regions.

Many mathematical models and data analytics tools have been proposed to understand the evolution of the COVID-19 pandemic throughout the world, generally based on the SEIR classical compartmental model (see [12] for an overview of mathematical modelling applications to COVID-19). We found in the literature different models for COVID-19, developed mainly to study the influence of social distancing and non-pharmaceutical interventions on disease progression [13, 14]. The study in [2] promoted non-pharmaceutical interventions, whereas [15] assessed the effect of such measures in Europe. Researchers evaluated the effectiveness of long-term on-off lock-down policies [16], and pursued optimal trade-offs between economics and healthcare concerns [17]. Like most of the literature, these works did not consider the possibility of reinfection or multiple viral strains. Similarly, these possibilities were also disregarded in investigations of optimal strategies to exit lock-down, which also neglected the possibility of multiple waves of infection [18, 19].

To shape public policy, we also need a thorough understanding of the pandemic. This includes mapping the genomics of viral strains [20, 21]. Indeed, researchers recently mapped new COVID-19 strains in the United Kingdom [22] and South Africa [23], which have rapidly spread around the globe. In Brazil, initial studies revealed more than 100 COVID-19 viral strains [6, 24, 25], three of which survived. Such a reduction in genetic diversity has been attributed to the social isolation measures in that country [26]. Recently, a variant known as P.1 (lineage 501Y.V3 or Brazilian variant) has become prevalent in Brazil. Sequencing results from the state of Amazonas, Brazil—where the variant was first detected—identified P.1 in about 42% of the samples tested in December 2020 [27]. This variant is believed to have a high potential for reinfection [6].

Another important challenge to modellers is that the immune response to COVID-19 is not uniform [28], may reportedly wane over time [29–31] and reinfection is possible [4, 5]. Furthermore, the same patient may be infected by different strains of the virus [32, 33]. As stated in [34], a thorough understanding of reinfection is essential for understanding the spread of the disease, as future global challenges include containing epidemics with reinfection [35].

For data-based modelling, we refer the interested reader to [36]. This work utilised available databases and the classical SIR (Susceptible, Infected, Recovered) framework to estimate the number of COVID-19 reinfections from empirical data. Additionally, [37] discusses the challenges of applying data-science to COVID-19, which include reconciling conflicting and inaccurate reports, partly due to asymptomatic infections and insufficient testing.

Although COVID-19 reinfection and multiple viral strains have received increased attention in the literature, mathematical modelling that incorporates these characteristics is still scarce. A general two-strain model searched for stability conditions and assessed a quarantine strategy to curb COVID-19 in Morocco [38]. More generally, viral reinfection is often studied with emphasis on stability conditions and disease-free equilibrium [39]. Specifically, [40] featured a SEIR model for swine influenza and evaluated prescribed vaccination strategies. Finally, a simpler SIR model studied the dynamics of two viral strains, considering that the second strain appears after the first strain reaches equilibrium [41]. In general, whilst these models examine long-term stability, they do not incorporate decision support tools and optimisation.

To support decision making, optimal control approaches have been proposed to promote compromises between COVID-19 infection levels and economic consequences of non-pharmaceutical interventions [17, 42, 43]. The control may comprise a proportional reduction in infection [17, 43] or include quarantine, isolation, and public health education [42]. Although these models do not consider reinfection and multiple viral strains, they do provide interesting

insights. An interesting insight is that, to preserve healthcare systems and leverage control options late in the epidemics, we need high levels of control from the outset [43]. This is consistent with the empirical results in [16], which combined the SEIR model with on/off lockdown policies to assess the impact of spreading the outbreak across several waves of decreasing amplitude. The results showed that there would exist multiple waves requiring flattening over time in the absence of effective medication, an appropriate vaccine, or the development of herd immunity.

Whereas models considering multiple viral strains are rare, the literature contains optimal control approaches based on classical epidemiological models for two viral strains [44, 45]. These are general epidemiological models, i.e. not specifically tailored for a given epidemic, that do not consider reinfection. A limiting feature of the model in [44], however, is that it relies on curative treatment. In contrast, the discrete network-based model in [45] relies on separate control measures for each strain.

To the best of our knowledge, this is the first paper to simultaneously consider multiple viral strains, reinfection, and optimal control. Amongst the novel contributions of this work, we generalise the preceding literature [38, 44, 45] by considering not only two but any number of viral strains. Based on the SEIR framework, the model innovates by considering waning immunity over time, as well as reinfection, which can considerably increase the infection levels. Finally, we propose a novel optimal control approach whereby a proportional reduction of the infection rate by mitigation measures (such as non-pharmaceutical interventions) incurs an exponentially increasing cost. This approach is more realistic than assuming linear or quadratic costs [42, 43], once it is increasingly difficult—and therefore costlier—to reduce transmission after mitigating measures are already in place. The proposed approach seeks a compromise between the overall number of deaths and the intervention costs over a prescribed horizon.

In addition to the methodological innovations, we also contribute by providing a more realistic framework for epidemic modelling that avoids the sometimes optimistic assumptions of perennial immunity and a single viral strain. The framework also includes an optimal control formulation that enables decision makers to define a compromise between loss of life and economic consequences over a prolonged time horizon. It is worth emphasising that, although the COVID-19 pandemic is certainly a motivation, we propose a general framework for a realistic modelling of the spread of viral diseases. As such, it includes the possibility of reinfection due to waning immunity, as well as multiple viral strains and optimal control.

The remainder of this paper is organised as follows. We firstly introduce the proposed multi-strain model with reinfection and analyse its equilibrium points and the reproductive number. Then, we propose a novel optimal control formulation for the multi-strain model, which is solved to derive the optimal control strategy over a prescribed time horizon. Next, we propose a series of experiments designed to illustrate the system's behaviour in the presence of two strains, with and without mitigation. The experiments consider the largely unmitigated COVID-19 spread in the state of Amazonas, Brazil [3, 46, 47], where the epidemic gave rise to two distinct viral strains in 2020 [27]; started in April 2021, the vaccination had no effect on the first two waves. Furthermore, the estimated 75% attack rate during the first wave [46] implies the second peak is mainly due to the second strain. For the unmitigated epidemic, the model's results are compatible with the observed outbreak and explain the attack rate observed in a serological study. To further validate our model, we apply it to the second and third waves of COVID-19 in England, where distinct mitigation measures were applied. The results are compatible with the infection levels observed in the country. We also derive and interpret optimal control strategies for the Amazonas epidemic, over a two-year horizon and under distinct mitigation costs and two viral strains. Finally, we present our concluding remarks.




Fig 1. The classical SEIR model.

<https://doi.org/10.1371/journal.pone.0257512.g001>

Preliminaries

Introduced in the first half of the 20th century [8], the classical SEIR model divides the population into four compartments: *susceptible* (S), *exposed* (E), *infected* (I) and *removed* (R). The system's dynamics follows the equations below and is illustrated in Fig 1, which depicts the transitions among the compartments.

$$\begin{aligned}\dot{S}(t) &= -\beta S(t)I(t) \\ \dot{E}(t) &= \beta S(t)I(t) - \sigma E(t) \\ \dot{I}(t) &= \sigma E(t) - (\mu + \gamma)I(t) \\ \dot{R}(t) &= \gamma I(t)\end{aligned}$$

As observed in the equations above and in Fig 1, healthy individuals are *susceptible* to the disease and can acquire it upon encountering *infected* individuals. The total number of encounters is SI and the rate of transmission per encounter is β . Hence, *susceptible* individuals become *exposed* to the disease at an overall rate βSI . *Exposed* individuals have acquired the disease in a latent state; the disease is not manifested nor can be transmitted while the latency period lasts. As the duration of the latency period is $\frac{1}{\sigma}$, *exposed* individuals become *infected* at an overall rate σE . The infection lasts $\frac{1}{\gamma}$ units of time, therefore *infected* individuals become *removed* at an overall rate γI . Alternatively, *infected* individuals may die, at rate μ . Finally, *removed* individuals have acquired immunity through infection and can no longer be affected by the illness.

Observe in Fig 1 that the dynamics of the classical SEIR model imply perennial immunity, as removed individuals can no longer be affected by the disease. Another important characteristic of the model is that it considers a single viral strain. In the next section, we will introduce a generalised model that considers multiple strains, waning immunity and a control variable $u(t)$ to account for mitigation measures.

Proposed mathematical model

Let $V = \{1, \dots, n\}$ be the set of virus strains circulating in the population, and let $j \in V$ denote a particular strain. For each $j \in V$ and time $t \geq 0$, let $S_j(t)$, $E_j(t)$, $I_j(t)$ and $R_j(t)$ respectively denote the number of susceptible, exposed, infected and removed (recovered and immune) individuals in the population at time t . In addition, $P(t)$ denotes the total population at time $t \geq 0$.

The susceptible population $S_j(t)$ includes all individuals that are not immune to strain $j \in V$ at time $t \geq 0$ and therefore can catch the disease. In turn, $E_j(t)$ comprises all individuals that have been recently contaminated by strain j but are currently in the latency period and therefore have not yet manifested the disease and become infectious. Finally, $I_j(t)$ counts all individuals that have caught and manifested the strain j and are still suffering from it, whereas $R_j(t)$ denotes the total number of individuals that are recovered and immune to strain j at time t .

The proposed multi strain model follows Eqs (1)–(5) below:

$$\dot{P}(t) = -\sum_{j=1}^n \mu_j I_j \tag{1}$$

$$S_j(t) = P(t) - E_j(t) - I_j(t) - R_j(t) \tag{2}$$

$$\dot{E}_j(t) = (1 - u(t))\beta_j S_j(t)I_j(t) - \sigma_j E_j(t), \tag{3}$$

$$\dot{I}_j(t) = \sigma_j E_j(t) - (\mu_j + \gamma_j)I_j(t), \tag{4}$$

$$\dot{R}_j(t) = \gamma_j I_j(t) - \delta_j R_j(t), \tag{5}$$

where $S_j(0) \leq P(0), \forall j \in V$.

Consider the dynamics of a given strain $j \in V$. Observe from Eq (3) that susceptible individuals can contract this strain when in contact with a contagious carrier belonging to the infected population. The rate of infection is $\beta_j > 0$ and $u(t) \in [0, 1]$ emulates the mitigation effect at time $t \geq 0$: $u(t) = 1$ indicates 100% effective mitigating measures and $u(t) = 0$ represents the absence of non-pharmaceutical interventions, whereas $u(t) \in (0,1)$ indicates partially effective measures to limit the spread of the disease. The first term in the right hand side of (3) represents the formerly susceptible individuals that have just been infected, whereas the second term indicates the exposed individuals that have just manifested the once latent disease. The latter enter the infected compartment in the right hand side of Eq (4). The second term in the right hand side of (4) represents infected individuals that recover—at rate $\gamma_j > 0$, or die—at rate $\mu_j \geq 0$. Finally, each newly recovered individual moves to the *removed* compartment—first term of the right hand side of (5). The second term in the right hand side of (5) represents the loss of immunity over time. Finally, Eq (2) keeps track of the individuals that are currently susceptible to strain $j \in V$, whereas Eq (1) monitors the evolution of the total population over time. Table 1 describes the system’s parameters.

Remark 1 Observe in the system (1)–(5), that an individual is susceptible to all strains $j \in V$. For a particular strain $j \in V$, Eq (2) ensures that only the individuals that are currently exposed to or infected with strain j are left out of the susceptible population for that strain (S_j), as well as

Table 1. Parameters for multi-strain dynamics.

Parameter	Description	Unit
β_j	Transmission rate of strain j	transmissions/encounter
σ_j	Inverse of the latency period of strain j	days ⁻¹
γ_j	Recovery rate for strain j	days ⁻¹
δ_j	Rate of immunity loss for strain j	days ⁻¹
μ_j	Death rate due to strain j	days ⁻¹
$u(t)$	Mitigation (lock-down) effect at time t	-

<https://doi.org/10.1371/journal.pone.0257512.t001>

those currently in the removed compartment of that strain (R_j). The latter have been recently infected with this strain and are currently immune to it. It is worth reinforcing that this immunity wanes over time at a rate δ_j —Eq (5).

Remark 2 A key innovation of the model is to consider multiple viral strains. Observe that the system of Eqs (1)–(5) includes an arbitrary number (n) of viral strains. Another innovation is the possibility of reinfection due to waning immunity, which is contemplated in the last term of Eq (5). Therefore, at each time t , a fraction $\delta_j R_j$ of the individuals currently immune to strain j become susceptible again to this strain and join the susceptible population S_j ; as R_j decreases, S_j increases by the same amount in Eq (2).

The equilibrium points

To simplify our analysis, in this section we assume a constant control, i.e. $u(t) = u \in [0, 1]$, $\forall t \geq 0$. A simple inspection to the system of Eqs (1)–(5) yields

$$\dot{S}_j(t) = -(1 - u)\beta_j S_j(t)I_j(t) + \delta_j R_j(t) - \sum_{i=1, i \neq j}^n \mu_i I_i(t). \tag{6}$$

Hence, it is not hard to verify that the trivial equilibrium point is the infection free point, with

$$E_j(\infty) = I_j(\infty) = R_j(\infty) = 0, \quad S_j(\infty) = \bar{S}_j \geq 0, \quad P(\infty) \geq 0. \tag{7}$$

To calculate the non-trivial equilibrium, we start with the case of two strains below.

Theorem 1 Suppose that there are $n = 2$ viral strains. Then, besides the trivial equilibrium point in Eq (7), the system has a non-trivial equilibrium point with $I_1 \leq 0$.

From Theorem 1, it follows that the non-trivial equilibrium point of a two-strain model is biologically infeasible, and therefore of no practical interest. Theorem 2 below generalises this result for multiple strains, i.e. $|V| > 2$.

Theorem 2 Suppose that $n > 2$. Then, besides the trivial equilibrium point in Eq (7), the system has a non-trivial equilibrium point with $I_j \leq 0, \forall j \in \{1, \dots, n\}$.

Theorem 2 therefore implies that the non-trivial equilibrium point is biologically infeasible and of no practical use for any number of different strains. In the remainder of this paper, we will only consider biologically feasible solutions. The proofs of Theorems 1 and 2 can be found in Appendix A of [S1 Appendix](#).

Stability

Considering that only the trivial equilibrium points are of biological interest, this section analyses the stability solely with respect to these points.

To prove stability we need to show that the real part of the eigenvalues Jacobian matrix associated with the system and applied to the trivial equilibrium are negative. From the conditions of stability we can define the reproduction number (see the proof in the Appendix A of [S1 Appendix](#)),

$$R_0 = \max_{j=1, \dots, n} \frac{(1 - u)\beta_j \bar{S}_j}{\mu_j + \gamma_j}. \tag{8}$$

We can say that the trivial equilibrium point (without infection) is locally asymptotically stable if $R_0 < 1$. Hence, Eq (8) implies a minimum level of constant lock-down effect $u \in [0, 1]$ to stabilise the system. Observe that, since the lock-down effect applies to all viral strains, it suffices to stabilise the system with respect to the most transmissible strain.

In the next section, we expand the analysis to search for time varying lock-down effects with a view to optimising the long-term cost of non-pharmaceutical (lock-down) interventions.

Optimal mitigation strategies

To control the spread of the disease in the population, the proposed strategy considers an isolation level of the population $u(t)$, $t \geq 0$ at any time t . To account for the time-varying control, let us rewrite the system of Eqs (1)–(6) as follows:

$$\dot{P}(t) = -\sum_{j=1}^n \mu_j I_j \tag{9}$$

$$\dot{S}_j(t) = -(1 - u(t))\beta_j S_j(t)I_j(t) + \delta_j R_j(t) - \sum_{i=1; i \neq j}^n \mu_i I_i \tag{10}$$

$$\dot{E}_j(t) = (1 - u(t))\beta_j S_j(t)I_j(t) - \sigma_j E_j(t), \tag{11}$$

$$\dot{I}_j(t) = \sigma_j E_j(t) - (\mu_j + \gamma_j)I_j(t), \tag{12}$$

$$\dot{R}_j(t) = \gamma_j I_j(t) - \delta_j R_j(t), \tag{13}$$

To find a meaningful trade-off between the cost of the control, i.e. lock-down measures or non-pharmaceutical interventions, and the cost of elevated infection levels to the healthcare system and the population in general, we define the following functional cost:

$$J(P, u) = c_1 P - e^{c_2 u}, \quad 0 \leq u \leq 1, \tag{14}$$

where $c_1 > 0$ and $c_2 > 0$ are scalar parameters.

Recall that in the revised formulation Eqs (9)–(13), $u(t) = 0$ indicates no lock-down and $u(t) = 1$ corresponds to full lock-down. Observe that the cost in (14) grows with the population size and decreases as a function of the control u . While increasing u decreases the functional, it also implies a decrease in the number of infections and, therefore, deaths. And less deaths imply an increased total population, thus increasing the functional. Observe also that the cost of control increases exponentially in the feasible interval $[0, 1]$, to mimic the fact that extra mitigation measures tend to become increasingly costly.

Let $\psi = \{u(t), t \in (0, T): u(t) \in [0, 1]\}$ be a feasible lockdown strategy and let Ψ denote the set of all feasible strategies. For each control strategy $\psi \in \Psi$, let

$$J(\psi) = \int_0^T J(P(s), u(s)) ds \tag{15}$$

denote the overall cost of the strategy. The optimal control problem then becomes:

$$\begin{aligned} &\text{Maximise } J(\psi), \psi \in \Psi \\ &\text{subject to (9) – (13).} \end{aligned} \tag{16}$$

The overall objective in (16) is to minimise the number of deaths over time, which is equivalent to maximising the population, whilst also accounting for the cost of lock-down measures represented by the negative term in (14). Theorem 3, in Appendix B of [S1 Appendix](#),




Fig 2. Dynamic behaviour for two strains in Amazonas, Brazil (Experiment 1).

<https://doi.org/10.1371/journal.pone.0257512.g002>

guarantees that an optimal solution exists which satisfies (16), and derives the optimal mitigation strategy.

Numerical experiments

To better understand the long-term behaviour of the system (1)–(5), we performed an experiment -termed *Experiment 1*—based on the outbreak at the state of Amazonas in Brazil, an example with reinfection and two viral strains [3]. The experiments used $R_0 = 3$ as estimated for the state, which yields a 67% overall infection rate [47], just short of the estimate of 76% from a serological study [46]; as, according to [3], this estimate may have been biased due to an adjustment of the observed prevalence of 52.5% due to waning immunity. A second strain called P.1 was detected in the state in December 2020 [27]. Fig 2 depicts the results of *Experiment 1* and Table 2 conveys the model parameters and initial conditions.

As the epidemic in Amazonas was largely unmitigated, with a high seroprevalence at the second peak [3, 46], it is consistent with a two-strain outbreak with reinfection, as demonstrated in Fig 2. The stability observed after the first wave can be explained by reinfection from the first strain, whereas at the peak of the second strain more cases are observed as they include patients with both strains. In the experiment, we assumed that the second strain commenced six months (180 days) after the epidemic’s outset. It is worth of emphasis that the removed

Table 2. Parameters for Experiment 1.

Parameter	Value
$\beta_1 = \beta_2$	$3.447 \cdot 10^{-8}$
$\sigma_1 = \sigma_2$	$\frac{1}{7} \text{ days}^{-1}$
$\gamma_1 = \gamma_2$	$\frac{1}{21} \text{ days}^{-1}$
$\delta_1 = \delta_2$	$\frac{1}{150} \text{ days}^{-1}$
$\mu_1 = \mu_2$	$1.152 \cdot 10^{-5} \text{ days}^{-1}$
$u(t)$	0—no mitigation.
Initial Conditions	
Strain 1	Strain 2
$S_1(0) = 4,144,342$	$S_2(t) = 4,144,597, t < 180$
$E_1(0) = 252$	$E_2(t) = 0, \forall t \leq 180,$
$I_1(0) = 2$	$I_2(180) = 1, I_2(t) = 0, \forall t < 180$
$R_1(0) = 1$	$R_2(t) = 0, \forall t \leq 180$

<https://doi.org/10.1371/journal.pone.0257512.t002>

population stabilises around 50%, in line with the antibody prevalence of 52.5% observed in [46].

Considering that the two strains are similar, the result in Fig 2 is intuitive. We observe that the second strain is simply a delayed version of the first outbreak, which makes sense given the similar parameters. The important feature here is that the second strain will add to the burden on the healthcare system, generating a second peak, increasing the levels of contamination and eventually doubling the burden. Notice, however, that at the peak of the second strain, most of the infections will be from this strain before the system eventually stabilises. Observe also the reduction of the population, which significantly increases after the second strain, as we accumulate deaths from both viral variants. We argue that this should be considered to inform the decision makers. Indeed, strategies to prevent different strains from entering a given territory by enforcing testing upon arrival can be an important part of mitigation policies.

The results corroborate those found in a genetic study in the state of Amazonas, from March 2020 to January 2021 [48]. The study reveals the prevalence of three correlated viral lineages (B.1.1.95, B.1.1.28 and B.1.1.33) up to the emergence of variant P.1. Whilst reinfection due to the persistence of the first lineages was the motor of the sustained infection levels up to December 2020, it was the genetically diverse variant P.1 that drove the second wave that started in December 2020.

An example with control: The case of England

To further validate the proposed approach, *Experiment 1a* is based on the second and third COVID-19 waves in England, from September 2020 to April 2021. Variant *Alpha* was first detected in the end of September (<https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data>). To calibrate the model, we used the results of the weekly survey conducted in England since mid-2020 (<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyypilot/previousReleases>). The survey provides weekly estimates of the COVID-19 infection levels in the country, as well as a 95% confidence interval, which is depicted in Fig 3 for the selected period. Table 3 features the parameters and initial conditions of the experiment. The R [49] code used to simulate the example is available as supplementary material.

Observe in Fig 3 that the overall number of infections from the model is consistent with the infection levels observed in the COVID-19 survey in England. The model is able to follow the estimated number of infections whilst also accounting for the varying mitigation measures observed within the time horizon. The values of $u(t)$ in Table 3 can be seen as estimates of the overall effect of the mitigation measures in place. The larger values correspond to the two




Fig 3. Infected population for Experiment 1a.

<https://doi.org/10.1371/journal.pone.0257512.g003>

Table 3. Parameters for Experiment 1a.

Parameter	Value
$\beta_1 = \beta_2$	$2.55 \cdot 10^{-9}$
$\sigma_1 = \sigma_2$	$\frac{1}{7} \text{ days}^{-1}$
$\gamma_1 = \gamma_2$	$\frac{1}{21} \text{ days}^{-1}$
$\delta_1 = \delta_2$	$\frac{1}{150} \text{ days}^{-1}$
$\mu_1 = \mu_2$	$1.152 \cdot 10^{-5} \text{ days}^{-1}$
$u(t)$	$\begin{cases} 0.18, & 0 < t < 60 \\ 0.82, & 60 \leq t < 90 \\ 0.20, & 90 \leq t < 116 \\ 0.85, & t \geq 116 \end{cases}$
Initial Conditions	
Strain 1	Strain 2
$S_1(0) = 55,932,799$	$S_2(t) = 56,000,000, t < 30$
$E_1(0) = 16,800$	$E_2(30) = 11200, E_2(t) = 0, \forall t \leq 180$
$I_1(0) = 50,400$	$I_2(30) = 28000, I_2(t) = 0, \forall t < 30$
$R_1(0) = 1$	$R_2(t) = 0, \forall t \leq 30$

<https://doi.org/10.1371/journal.pone.0257512.t003>

lock-down periods observed from September 2020 to April 2021: a one-month lock-down in October and another lock-down period starting in late December, which was still in place in April 2021.

For the sake of completeness, Fig 4 details the evolution of the exposed, infected, and removed populations for Experiment 1a. As expected, one can observe two steep increases between lockdown periods and two periods of steady decrease as the lock-downs were put in place.

Optimal mitigation strategies

This section provides insights into the effect of the optimal control policy derived in Theorem 3 into the dynamics of the system over a two-year horizon. The first simulation is Experiment 2, which introduces optimal control at the outset of the epidemic; the parameters of the first strain appear in Table 2. For this experiment, we use $c_1 = 1$ and $c_2 = \frac{\ln(P(0))}{2}$ in the functional in Eq (14). Depicted in Fig 5, the results show that the optimal control prevents about 60% of




Fig 4. Dynamic behaviour for two strains in England (Experiment 1a).

<https://doi.org/10.1371/journal.pone.0257512.g004>




Fig 5. Optimal control policy from the epidemic's outset (*Experiment 2*), with $c_1 = 1$ and $c_2 = \frac{\ln(P(0))}{2}$.

<https://doi.org/10.1371/journal.pone.0257512.g005>

Table 4. Initial conditions for *Experiment 3*.

Initial Conditions	
$S_1(0) = 2,238,082$	$S_2(0) = 4,144,342$
$E_1(0) = 41446$	$E_2(0) = 252$
$I_1(0) = 207230$	$I_2(0) = 2$
$R_1(0) = 1657839$	$R_2(0) = 1$

<https://doi.org/10.1371/journal.pone.0257512.t004>

the contacts in the early stages and slowly decreases with time. It curbs the epidemic from the outset and therefore inhibits the emergence of the second strain.

Experiment 3 assumes stabilisation of the first strain around the values observed in *Experiment 1*, as well as the emergence of a second strain. In other words, this simulates a delayed mitigation policy that starts shortly after the emergence of strain 2. We use the parameters from [Table 2](#) and the initial conditions in [Table 4](#), and make $c_1 = 1$ and $c_2 = \frac{\ln(P(0))}{2}$ in [Eq \(14\)](#). Observe in [Fig 6](#) that the optimal control starts close to one (full lockdown) to stabilise the first strain; it is continuously reduced over time as the epidemic is effectively mitigated. It is also noteworthy that the control dissipates strain 2 from the outset, as it starts with lower infection levels. Note also that the population remains close to the original levels, indicating




Fig 6. Optimal control policy and system evolution for *Experiment 3*, with $c_1 = 1$ and $c_2 = \frac{\ln(P(0))}{2}$.

<https://doi.org/10.1371/journal.pone.0257512.g006>

Table 5. Cost parameters c_1 and c_2 to be evaluated.

Case	A	B	C	D	E
c_1	1	2	1	3	3
c_2	$\ln(P(0))$	$\ln(P(0))$	$\frac{\ln(P(0))}{3}$	$\ln(P(0))$	$\frac{\ln(P(0))}{3}$

<https://doi.org/10.1371/journal.pone.0257512.t005>

the optimal policy’s effective prevention of deaths with respect to the unmitigated scenario in *Experiment 1*.

Varying parameter c_1 and c_2 . We now consider the effects varying parameters c_1 and c_2 in the following experiments, under the same initial conditions and parameters in *Experiment 3*. The cost parameters tested appear in [Table 5](#).

[Fig 7](#) depicts the results for Case A in [Table 5](#). As expected, doubling the cost of control (c_2) with respect to *Experiment 3* in ([Fig 6](#)) results in a decrease of the control levels, which start at around 0.6 and slowly decrease over time. That results in a slower stabilisation of the first strain, with higher levels of infection over time. Nonetheless, the control suffices to curb the epidemic and prevent the spread of the second strain, which remains under control over the entire horizon.

[Fig 8](#) depicts the results for Case B. It uncovers the effect of doubling c_1 with respect to case A, maintaining the same value for c_2 . We observe a slight increase in the control levels, as the relative importance of the control costs is decreased. The increase results in slightly lower levels of infections over time for strain 1. The susceptible population therefore increases slightly




Fig 7. Results for Case A, with $c_1 = 1$ and $c_2 = \ln(P(0))$.

<https://doi.org/10.1371/journal.pone.0257512.g007>




Fig 8. Results for Case B, with $c_1 = 2$ and $c_2 = \ln(P(0))$.

<https://doi.org/10.1371/journal.pone.0257512.g008>




Fig 9. Results for Case C, with $c_1 = 1$ and $c_2 = \frac{\ln(P(0))}{3}$.

<https://doi.org/10.1371/journal.pone.0257512.g009>

with respect to Case A, whereas the removed population slightly decreases. As in Case A, strain 2 remains under control for the entire horizon.

Fig 9 depicts the results for Case C. It uncovers the effect of reducing c_2 to a third of that in Case A, maintaining the same value for c_1 . We observe maximum control levels (i.e. full lockdown) for about 60 days to contain the first strain more rapidly, as the relative cost of control decreased. The control is then gradually relaxed as time elapses. The increased control levels result in the near extinction of both strains after about 125 days. Mitigation is then maintained to avoid a resurgence of the disease, as even small levels of infection can lead to another wave. In practice, policy makers may choose more targeted approaches after the infection levels reach a sufficiently small threshold. In that case, the optimal policy will provide guidance as to the desired mitigating effect of such measures to prevent an additional outbreak.

Case D sees c_1 triple with respect to Case A, maintaining the same value of c_2 . The results in Fig 10 see a slight increase in control with respect to Cases A and B, with a corresponding slight decrease in infection levels. Therefore, the susceptible population experiences a slight growth with respect to Cases A and B, whereas the removed population slightly falls. As before, strain 2 remains controlled over the entire horizon.

Finally, Case E triples c_1 with respect to Case A while reducing c_2 by two thirds. As depicted in Fig 11, this results in a maximum level of control until both strains are virtually extinguished. Then, the control is quickly reduced to about 0.6 and from there it is slowly reduced to prevent a resurgence. With respect to Case C, we notice a longer time in full lockdown, as the cost of control is decreased, although both strategies quickly extinguish the disease. Once again, the optimal control levels after stabilisation can guide decision makers as to the desired level of mitigation of possibly more targeted prevention policies to prevent resurgence after the epidemic is controlled.

The experiments show that we can derive an optimal control policy to control the outbreak whilst considering both reinfection and multiple strains. *Experiment 2* in Fig 5 suggests that




Fig 10. Results for Case D, with $c_1 = 3$ and $c_2 = \ln(P(0))$.

<https://doi.org/10.1371/journal.pone.0257512.g010>




Fig 11. Results for Case E, with $c_1 = 3$ and $c_2 = \frac{\ln(P(0))}{3}$.

<https://doi.org/10.1371/journal.pone.0257512.g011>

applying an optimal control approach from the outset curbs the epidemic early and hinders the emergency of additional strains. However, the current pandemic vividly reminded us that policy makers may be slow to act and that may result in the appearance of multiple strains. The proposed model provides a general framework to tackle multiple strains and reinfection. *Experiment 3* and Cases A to E demonstrate the potential of the framework to support decision making under a more general setting with multiple strains and reinfections. It allows us to derive an optimal policy to mitigate the epidemic considering the spread of each strain and a prescribed trade-off between societal and economic factors, represented here by cost parameters c_1 and c_2 . Cases A to E illustrate how changes in the trade-off will affect the optimal mitigation levels, and consequently the infection levels over time; they also illustrate the need for a proactive policy to prevent the resurgence of the disease after the infection levels are controlled.

Limitations and future research

The proposed model is devised for emerging epidemics, hence one limitation is that it does not include vaccination. Even though one cannot count on the possibility of quickly developing a vaccine for an emerging epidemic, this possibility would include another level of generality to the model and should be considered in future research.

Another limitation that should be addressed in future research is the fact that the model does not consider cross-immunity between pairs of viral strains. This limitation did not influence our experiments, as the results are compatible with viral strains with no cross-immunity. Indeed, the steep increase in the infection levels in England and in Amazonas suggests very little or no cross-immunity, as confirmed by the experiments. However, although incorporating cross-immunity is not a trivial task, future studies should consider this possibility and suggest ways to include it in the mathematical model.

Concluding remarks

This paper proposed a novel modelling framework based on the classical SEIR model that considers multiple viral strains, reinfections, and optimal control. Whilst general and applicable to any viral epidemic, the framework was validated in light of the current COVID-19 pandemic, which has challenged healthcare systems around the globe. We applied the approach to the outbreak in the state of Amazonas, Brazil and showed that the outbreak is consistent with a two-strain epidemic with reinfection. The results are interpretable, robust and highlight the

applicability of the model to contain viral outbreaks whilst considering the spread of multiple strains and establishing a trade-off between societal and economic impacts.

The results show that, with waning immunity and in the absence of mitigating measures, each viral strain will reach an equilibrium after the peak of infections. Whilst real-world data suggest that the peak is not manageable by any healthcare system in the world, it is evident that even the equilibrium may imply levels of infection that will challenge healthcare resources in many regions of the world. The results also suggest that, with insufficient mitigation measures, an epidemic with a second wave includes a second peak of infections that is higher than the first as it accumulates infections from both strains. Moreover, the number of deaths increases considerably after the emergence of the second strain.

Finally, we proposed and solved an optimal control problem to derive optimal mitigation measures whilst considering that the cost of mitigation grows exponentially as a function of the mitigation effort. Our simulations show that controlling the epidemic from the outset will quickly curb the outbreak, thereby hindering the emergence of different strains and avoiding the devastating effects of a prolonged epidemic. However, the current pandemic has shown that delayed and inadequate mitigation can lead to multiple strains and reinfection. This renders multi-strain models with reinfection invaluable to support decision making in real-world situations, where there is no guarantee that an epidemic will subside before multiple strains appear or that immunity will not wane over time.

We tested our model considering the absence of effective mitigation until the first strain stabilises, exploring the real-world case of the COVID-19 outbreak in the state of Amazonas, Brazil. We found that, when optimal control is activate just after the second strain emerges, it will stabilise the first strain while preventing an outbreak of the second strain. The long-term levels of the disease, as well as the magnitude of the mitigation effort will depend upon the perceived trade-off between societal and economic impacts, in the form of the parameters of the cost functional.

Supporting information

S1 Appendix.

(PDF)

S1 File.

(ZIP)

Author Contributions

Conceptualization: Edilson F. Arruda, Shyam S. Das, Dayse H. Pastore.

Methodology: Edilson F. Arruda, Claudia M. Dias, Dayse H. Pastore.

Software: Edilson F. Arruda.

Supervision: Edilson F. Arruda.

Validation: Dayse H. Pastore.

Writing – original draft: Edilson F. Arruda, Shyam S. Das, Claudia M. Dias, Dayse H. Pastore.

Writing – review & editing: Edilson F. Arruda, Claudia M. Dias.

References

1. Rodríguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease*. 2020; p. 101623. <https://doi.org/10.1016/j.tmaid.2020.101623> PMID: 32179124
2. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College London; 2020.
3. Sabino EC, Buss LF, Carvalho MPS, Prete CA Jr, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *The Lancet*. 2021; 397(10273):452–455. [https://doi.org/10.1016/S0140-6736\(21\)00183-5](https://doi.org/10.1016/S0140-6736(21)00183-5) PMID: 33515491
4. Bonifacio LP, Pereira APS, Araujo DCA, Balbao VMP, Fonseca BAL, Passos ADC, et al. Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil. *Revista da Sociedade Brasileira de Medicina Tropical*. 2020; 53. <https://doi.org/10.1590/0037-8682-0619-2020> PMID: 32965458
5. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *The Lancet Infectious Diseases*. 2021; 21(1):52–58. [https://doi.org/10.1016/S1473-3099\(20\)30764-7](https://doi.org/10.1016/S1473-3099(20)30764-7) PMID: 33058797
6. Resende PC, Motta FC, Roy S, Appolinario L, Fabri A, Xavier J, et al. SARS-CoV-2 genomes recovered by long amplicon tiling multiplex approach using nanopore sequencing and applicable to other sequencing platforms. *bioRxiv*. 2020; <https://doi.org/10.1101/2020.04.30.069039>
7. Bertozzi AL, Franco E, Mohler G, Short MB, Sledge D. The challenges of modeling and forecasting the spread of COVID-19. *Proceedings of the National Academy of Sciences*. 2020; 117(29):16732–16738. <https://doi.org/10.1073/pnas.2006520117>
8. Kermack WO, McKendrick AG, Walker GT. A contribution to the mathematical theory of epidemics. *Proceedings of the Royal Society of London Series A, Containing Papers of a Mathematical and Physical Character*. 1927; 115(772):700–721. <https://doi.org/10.1098/rspa.1927.0118>
9. Bacaer N. McKendrick and Kermack on epidemic modelling (1926–1927). 1st ed. Lodon: Springer; 2011.
10. Bootsma MCJ, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. *Proceedings of the National Academy of Sciences*. 2007; 104(18):7588–7593. <https://doi.org/10.1073/pnas.0611071104>
11. Carcione JM, Santos JE, Bagaini C, Ba J. A Simulation of a COVID-19 Epidemic Based on a Deterministic SEIR Model. *Frontiers in Public Health*. 2020; 8:1–13. <https://doi.org/10.3389/fpubh.2020.00230>
12. Wang J. Mathematical models for COVID-19: Applications, limitations, and potentials. *Journal of Public Health and Emergency*. 2020; 4. <https://doi.org/10.21037/jphe-2020-05>
13. Shao N, Zhong M, Yan Y, Pan H, Cheng J, Chen W. Dynamic models for Coronavirus Disease 2019 and data analysis. *Mathematical Methods in the Applied Sciences*. 2020; 43(7):4943–4949. <https://doi.org/10.1002/mma.6345> PMID: 32327866
14. Jia J, Ding J, Liu S, Liao G, Li J, Duan B, et al. Modeling the control of COVID-19: impact of policy interventions and meteorological factors. *Electronic Journal of Differential Equations*. 2020; 2020(23):1–24.
15. Flaxman S, Mishra S, Gandy A, Unwin H, Coupland H, Mellan T, et al. Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries. Imperial College London; 2020.
16. Tarrataca L, Dias CM, Haddad D, Arruda EF. Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil. *Journal of Mathematics in Industry*. 2021; 11(1):2. <https://doi.org/10.1186/s13362-020-00098-w>
17. Kantner M, Koprucki T. Beyond just “flattening the curve”: Optimal control of epidemics with purely non-pharmaceutical interventions. *Journal of Mathematics in Industry*. 2020; 10:23. <https://doi.org/10.1186/s13362-020-00091-3>
18. Ruktanonchai NW, Floyd JR, Lai S, Ruktanonchai CW, Sadilek A, Rente-Lourenco P, et al. Assessing the impact of coordinated COVID-19 exit strategies across Europe. *Science*. 2020; <https://doi.org/10.1126/science.abc5096> PMID: 32680881
19. Rawson T, Brewer T, Veltcheva D, Huntingford C, Bonsall MB. How and When to End the COVID-19 Lockdown: An Optimization Approach. *Frontiers in Public Health*. 2020; 8:262. <https://doi.org/10.3389/fpubh.2020.00262>
20. Callaway E. The coronavirus is mutating—does it matter? *Nature*. 2020; 585:174–177. <https://doi.org/10.1038/d41586-020-02544-6>

21. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020; 182(4):812–827.e19. <https://doi.org/10.1016/j.cell.2020.06.043> PMID: 32697968
22. Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. *The Lancet Respiratory Medicine*. 2021; [https://doi.org/10.1016/S2213-2600\(21\)00005-9](https://doi.org/10.1016/S2213-2600(21)00005-9) PMID: 33417829
23. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*. 2020; <https://doi.org/10.1101/2020.12.21.20248640>
24. Vieira DFB, Silva MAN, Garcia CC, Miranda MD, Matos AR, Caetano B, et al. Morphology and Morphogenesis of SARS-CoV-2 in Vero-E6 cells. *Research Square*. 2021; <https://doi.org/10.21203/rs.3.rs-40432/v1>
25. Voloch CM, da Silva RF, de Almeida LG, Cardoso CC, Brustolini OJ, Gerber AL, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *medRxiv*. 2020; <https://doi.org/10.1101/2020.12.23.20248598>
26. Candido DS, Claro IM, Jesus JG, Souza WM, Moreira FRR, Simon Dellicour S, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science*. 2020; 369(508):1255–1260. <https://doi.org/10.1126/science.abd2161> PMID: 32703910
27. Center for Disease Control and Prevention (CDC). Science Brief: Emerging SARS-CoV-2 Variants; 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants.html.
28. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine*. 2020; 26(8):1200–1204. <https://doi.org/10.1038/s41591-020-0965-6> PMID: 32555424
29. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJ, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiology*. 2020; 5:1598–1607. <https://doi.org/10.1038/s41564-020-00813-8> PMID: 33106674
30. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021; <https://doi.org/10.1126/science.abf4063> PMID: 33408181
31. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. *Nature Medicine*. 2020; 26(11):1691–1693. <https://doi.org/10.1038/s41591-020-1083-1> PMID: 32929268
32. Nonaka CKV, Franco MM, Graf T, A V A Mendes AVRSA, Giovanetti M, Souza BSF. Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in Brazil. *Preprints*. 2021; <https://doi.org/10.20944/preprints202101.0132.v1>
33. To KKW, Hung IFN, Ip JD, Chu AWH, Chan WM, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. *Clinical Infectious Diseases*. 2020; <https://doi.org/10.1093/cid/ciaa1275> PMID: 32840608
34. Overbaugh J. Understanding protection from SARS-CoV-2 by studying reinfection. *Nature Medicine*. 2020; 26(11):1680–1681. <https://doi.org/10.1038/s41591-020-1121-z>
35. Dawood AA. Mutated COVID-19 may foretell a great risk for mankind in the future. *New Microbes and New Infections*. 2020; 35:100673. <https://doi.org/10.1016/j.nmni.2020.100673>
36. McMahon A, Robb NC. Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected, Recovered) Modeling Using Empirical Infection Data. *JMIR public health and surveillance*. 2020; 6(4):e21168–e21168. <https://doi.org/10.2196/21168>
37. Latif S, Usman M, Manzoor S, Iqbal W, Qadir J, Tyson G, et al. Leveraging Data Science to Combat COVID-19: A Comprehensive Review. *IEEE Transactions on Artificial Intelligence*. 2020; 1(1):85–103. <https://doi.org/10.1109/TAI.2020.3020521>
38. Khyar O, Allali K. Global dynamics of a multi-strain SEIR epidemic model with general incidence rates: application to COVID-19 pandemic. *Nonlinear Dyn*. 2020; 102:489–509. <https://doi.org/10.1007/s11071-020-05929-4>
39. Frid H, Jabin PE, Perthame B. Global stability of steady solutions for a model in virus dynamics. *ESAIM: Mathematical Modelling and Numerical Analysis*. 2003; 37(4):709–723. <https://doi.org/10.1051/m2an:2003045>

40. Etbaigha F, Willms AR, Poljak Z. An SEIR model of influenza A virus infection and reinfection within a farrow-to-finish swine farm. *PLOS ONE*. 2018; 13(9):1–19. <https://doi.org/10.1371/journal.pone.0202493>
41. Fudolig M, Howard R. The local stability of a modified multi-strain SIR model for emerging viral strains. *PLoS ONE*. 2020; 12:e0243408. <https://doi.org/10.1371/journal.pone.0243408>
42. Bursac Z, Madubueze CE, Dachollom S, Onwubuya IO. Controlling the Spread of COVID-19: Optimal Control Analysis. *Computational and Mathematical Methods in Medicine*. 2020; 2020:6862516. <https://doi.org/10.1155/2020/6862516>
43. Perkins TA, España G. Optimal Control of the COVID-19 Pandemic with Non-pharmaceutical Interventions. *Bulletin of Mathematical Biology*. 2020; 82(9):118. <https://doi.org/10.1007/s11538-020-00795-y>
44. Bentaleb D, Harroudi S, Amine S, Allali K. Analysis and Optimal Control of a Multistrain SEIR Epidemic Model with Saturated Incidence Rate and Treatment. *Differential Equations and Dynamical Systems*. 2020; <https://doi.org/10.1007/s12591-020-00544-6>
45. Gubar E, Zhu Q, Taynitskiy V. Optimal Control of Multi-strain Epidemic Processes in Complex Networks. In: Duan L, Sanjab A, Li H, Chen X, Materassi D, Elazouzi R, editors. *Game Theory for Networks*. Cham: Springer International Publishing; 2017. p. 108–117.
46. Buss LF, Prete CA, Abraham CMM, Mendrone A, Salomon T, de Almeida-Neto C, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*. 2021; 371(6526):288–292. <https://doi.org/10.1126/science.abe9728> PMID: 33293339
47. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? *Nature Reviews Immunology*. 2020; 20(10):583–584. <https://doi.org/10.1038/s41577-020-00451-5>
48. Naveca FG, Gomes F, V, de Souza VC, Corado AL, Nascimento F, et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. *Nature Medicine*. 2021; 27:1230–1238. <https://doi.org/10.1038/s41591-021-01378-7> PMID: 34035535
49. R Core Team. R: A Language and Environment for Statistical Computing; 2021. Available from: <https://www.R-project.org/>.